This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| cyclophosphamide | |
|---|---|
| Name | Cyclophosphamide |
| IUPAC | 2-[bis(2-chloroethyl)amino]-tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide |
| Tradenames | Cytoxan, Neosar |
| Routes | Oral, intravenous, intraperitoneal |
| Class | Alkylating agent, nitrogen mustard analog |
cyclophosphamide Cyclophosphamide is an alkylating cytotoxic agent used in oncology and immunology. It is a prodrug metabolized in the liver to active metabolites that crosslink DNA, producing cell death in rapidly dividing cells. The drug appears in treatment protocols for hematologic malignancies, solid tumors, and autoimmune disorders.
Cyclophosphamide is used in treatment regimens for non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia, breast cancer, ovarian cancer, and multiple myeloma, often combined with protocols such as CHOP, ABVD, and CMF alongside agents like Adriamycin, Vincristine, Bleomycin, Methotrexate, and 5-Fluorouracil. In autoimmune diseases it is employed for severe systemic lupus erythematosus, vasculitis (including granulomatosis with polyangiitis and microscopic polyangiitis), and severe refractory rheumatoid arthritis when compared or sequenced with treatments such as Rituximab, Cyclosporine, Azathioprine, and high-dose corticosteroids used in regimens coordinated by institutions like the Mayo Clinic and Johns Hopkins Hospital. Cyclophosphamide is also used in conditioning regimens for allogeneic and autologous hematopoietic stem cell transplantation practiced at centers such as Fred Hutchinson Cancer Center and MD Anderson Cancer Center, and as part of mobilization protocols with agents like G-CSF and plerixafor modeled after transplantation protocols from Stanford University.
As a prodrug activated by hepatic cytochrome P450 enzymes including CYP2B6 and CYP3A4, cyclophosphamide is converted to 4-hydroxycyclophosphamide and aldophosphamide, which decompose to phosphoramide mustard and acrolein; phosphoramide mustard forms interstrand DNA crosslinks at guanine N7 positions, a mechanism shared with agents historically related to nitrogen mustards used during World War I and developed in the era of researchers linked to institutions like Yale University and Harvard Medical School. DNA crosslinking leads to inhibition of DNA replication and transcription, triggering apoptosis mediated by pathways involving p53 and caspases studied in laboratories at Cold Spring Harbor Laboratory and the Salk Institute. Acrolein, a urotoxic metabolite, is responsible for bladder toxicity; mitigation strategies reference studies from agencies including the National Cancer Institute.
Cyclophosphamide displays linear pharmacokinetics within therapeutic ranges and wide distribution into tissues with variability influenced by age, hepatic function, and coadministration with inhibitors or inducers of CYP450 such as Ketoconazole and Rifampin. Plasma protein binding is modest; renal excretion clears metabolites with half-life estimates derived from clinical pharmacology reports at centers like Cleveland Clinic. Drug interactions include potentiation of myelosuppression with concomitant use of agents such as Azathioprine and Trimethoprim-sulfamethoxazole and altered activation with CYP modulators referenced in formularies from World Health Organization treatment guidelines.
Dosing regimens vary by indication: in oncology, cyclophosphamide is administered orally or intravenously in single-agent or combination regimens with dosing schedules established by cooperative groups such as the European Society for Medical Oncology and the National Comprehensive Cancer Network; examples include bolus intravenous doses of 500–750 mg/m2 in CHOP protocols and high-dose regimens of several grams per square meter in conditioning protocols used at transplant centers like Dana-Farber Cancer Institute. For autoimmune indications, intravenous pulse regimens (e.g., 500–1000 mg monthly) or daily oral dosing (e.g., 1–2 mg/kg) are guided by trials coordinated by organizations including EULAR and American College of Rheumatology. Mesna uroprotection and aggressive hydration protocols recommended by institutions such as St. Jude Children's Research Hospital are used when high-dose cyclophosphamide is administered to prevent hemorrhagic cystitis.
Common toxicities include dose-dependent myelosuppression (neutropenia, thrombocytopenia, anemia) monitored with complete blood counts per standards at American Society of Hematology, alopecia, and nausea managed with antiemetics like Ondansetron. Urotoxicity including hemorrhagic cystitis due to acrolein is a serious complication historically observed in cohorts treated at hospitals such as Memorial Sloan Kettering Cancer Center; long-term risks include infertility and secondary malignancies such as therapy-related acute myeloid leukemia and bladder carcinoma reported in population studies by agencies including SEER Program at the National Cancer Institute. Pulmonary toxicity and cardiotoxicity have been documented in case series from centers like Toronto General Hospital.
Absolute contraindications include known hypersensitivity to cyclophosphamide formulations; caution and dose adjustments are required in patients with severe hepatic or renal impairment as outlined in guidance from regulatory agencies such as the U.S. Food and Drug Administration and the European Medicines Agency. Fertility preservation discussions referencing services at reproductive centers like Cleveland Clinic Fertility Center are advised before therapy in reproductive-age patients. Use in pregnancy is contraindicated due to teratogenicity documented in reports linked to Centers for Disease Control and Prevention surveillance; lactation guidance follows statements from organizations such as the American Academy of Pediatrics.
Cyclophosphamide was synthesized and developed in the mid-20th century building on nitrogen mustard research initiated during the interwar and World War II eras, with early clinical development conducted by investigators at institutions including Harvard Medical School and pharmaceutical companies later associated with modern firms such as Bristol-Myers Squibb and Roche. The drug's immunosuppressive properties were elucidated in trials at academic centers like University of California, San Francisco and contributed to its adoption in organ transplantation and autoimmune disease management, with pivotal clinical trials published through networks such as the National Institutes of Health cooperative groups. Continued refinements in dosing, uroprotection, and combination regimens reflect decades of research spanning oncology and rheumatology led by collaborative groups including SWOG and EORTC.
Category:Alkylating agents